Sun BioPharma, Inc. (OTCMKTS:SNBP) Files An 8-K Regulation FD DisclosureItem 5.02
Regulation FD Disclosure.
A copy of the press release announcing Ms. Horvath’s appointment, as described in Item 5.02 above, is furnished as Exhibit99.1 to this report on Form 8-K and incorporated herein by reference.
The information contained in this Item 5.02 and Exhibit 99.1 is being furnished and shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under Section18 and shall not be deemed to be incorporated by reference into the filings of the company under the Securities Act of 1933, as amended, or the Exchange Act.
|
Item 9.0 |
Financial Statements and Exhibits. |
(d) Exhibits
Sun BioPharma, Inc. ExhibitEX-99.1 2 ex_110311.htm EXHIBIT 99.1 ex_110311.htm Exhibit 99.1 Sun BioPharma,…To view the full exhibit click here
About Sun BioPharma, Inc. (OTCMKTS:SNBP)
Sun BioPharma, Inc., formerly Cimarron Medical, Inc., is a clinical stage drug development company. The Company is a biopharmaceutical company focused on developing therapies for pancreatic diseases. It is engaged in the commercial development of a polyamine analogue for pancreatic cancer and for a second indication in chronic pancreatitis. The Company’s products include SBP-101, SBP-102 and SBP-103. Its SBP-101 is a polyamine compound and exhibits specificity for the exocrine pancreas, with therapeutic potential for both pancreatic cancer and pancreatitis indications. It develops SBP-101 for the treatment of patients with pancreatic ductal adenocarcinoma. The SBP-102 product is in non-clinical feasibility evaluation for the treatment of patients with pancreatitis. The SBP-103 product is in non-clinical exploratory evaluation. The Company has enrolled first patient in its Phase I clinical trial of SBP-101 in patients with previously treated pancreatic cancer.